tility of the skin cancer quality of life impact tool (SCQOLIT)
- Conditions
- Topic: Cancer, DermatologySubtopic: Melanoma, Skin (all Subtopics)Disease: Skin, DermatologyCancerNon-melanoma skin cancer (NMSC)
- Registration Number
- ISRCTN15839666
- Lead Sponsor
- Oxford University Hospitals NHS Trust
- Brief Summary
1. 2016 results presented at ISOQOL in 2016: https://www.ncbi.nlm.nih.gov/pubmed/27650289 (added 29/04/2019) 2. 2017 results presented at the 97th Annual Meeting of the British Association of Dermatologists in 2017: http://www.bad.org.uk/shared/get-file.ashx?id=5779&itemtype=document (added 29/04/2019)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 300
1. Aged 18 years or above
2. Participant is willing and able to give informed consent for participation in the study.
3. All patients with a histopathological diagnosis of NMSC (primary or recurrent disease)
4. All treatments used for NMSC will be included in the study; excision, shave excision, curettage and cautery, Mohs micrographic surgery, photodynamic therapy and topical treatments e.g. imiquimod cream
1. Concurrent internal malignancy as this is likely to significantly influence quality of life (QOL)
2. Patients referred on to other specialties for management of their skin cancer e.g. Plastic surgeons / Clinical oncology
3. Other significant dermatological diseases e.g. severe inflammatory or blistering skin conditions as this may influence QOL
4. Inability to consent for themselves
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Acceptability of SCQOLIT tool as determined by analysis of patients participation rates and qualitative analysis of patient and staff preferences at the end of the study.
- Secondary Outcome Measures
Name Time Method Psychometric properties of SCQOLIT tool are measured at baseline, 3 months and 6-9 months.